Stalevo 200 mg/50 mg/200 mg film-coated tablets
Spain
Table of Contents
Patient Information Leaflet
Introduction
Patient Information Leaflet
Stalevo 200mg/50mg/200mg film-coated tablets
Levodopa/carbidopa/entacapone
Read this entire leaflet carefully before you start taking this medicine, as it contains important information for you.
- Keep this leaflet, as you may need to read it again.
- If you have any questions, ask your doctor or pharmacist.
- This medicine has been prescribed for you only, and you should not give it to others, even if they have the same symptoms as you, because it may harm them.
- If you experience any adverse effects, consult your doctor or pharmacist, even if they are effects not listed in this leaflet. See section 4.
Leaflet Contents
- What Stalevo is and what it is used for
- What you need to know before taking Stalevo
- How to take Stalevo
- Possible adverse effects
- How to store Stalevo
- Contents of the pack and other information
1. What Stalevo is and what it is used for
Stalevo contains three active substances (levodopa, carbidopa and entacapona) in a single film-coated tablet. Stalevo is used to treat Parkinson's disease.
Parkinson's disease is caused by low levels in the brain of a substance called dopamine. Levodopa increases the amount of dopamine and thereby reduces the symptoms of Parkinson's disease. Carbidopa and entacapone enhance the anti-Parkinson effects of levodopa.
2. What you need to know before taking Stalevo
Do not take Stalevo if:
- you are allergic to levodopa, carbidopa, or entacapone, or to any of the other ingredients of this medicine (listed in section 6)
- you have narrow-angle glaucoma (an eye disorder)
- you have a tumor of the adrenal glands
- you are taking certain medicines to treat depression (combinations of selective MAO-A and MAO-B inhibitors, or non-selective MAO inhibitors)
- you have ever had neuroleptic malignant syndrome (NMS – a rare reaction to medicines used in the treatment of serious mental disorders)
- you have ever had non-traumatic rhabdomyolysis (a rare muscle disorder)
- you have severe liver disease.
Warnings and precautions
Talk to your doctor or pharmacist before starting Stalevo if you have or have ever had:
- a heart attack or any other heart or blood vessel disease, including arrhythmias
- asthma or any other lung disease
- any liver problems, as your dose may need to be adjusted
- any kidney disease or hormone-related disorder
- stomach ulcer or seizures
- prolonged diarrhea. Consult your doctor, as this may be a sign of colitis
- any form of serious mental disorder, such as psychosis
- open-angle glaucoma, as your dose may need to be adjusted and your intraocular pressure monitored.
Talk to your doctor if you are taking:
- antipsychotics (medicines used to treat psychosis)
- any medicine that may cause a drop in blood pressure when standing up from a chair or bed. Be aware that Stalevo may worsen these reactions.
Talk to your doctor if, during treatment with Stalevo, you:
- experience marked muscle stiffness, violent muscle contractions, tremors, agitation, confusion, fever, rapid pulse, or large fluctuations in blood pressure. If any of these occur, contact your doctor immediately
- feel depressed, have suicidal thoughts, or notice unusual changes in your behaviour
- find you fall asleep suddenly or feel very drowsy. If this happens, do not drive or operate tools or machinery (see also section “Driving and use of machines”)
- begin to notice uncontrolled movements or they worsen. If this occurs, your doctor may need to change your dose
- experience diarrhea: weight should be monitored to prevent excessive weight loss
- experience progressive loss of appetite, asthenia (weakness, exhaustion), and weight loss over a relatively short period. In such cases, a full medical evaluation including liver function tests should be considered
- are considering stopping Stalevo; refer to the section “If you stop taking Stalevo”.
Inform your doctor if you, or your family/caregiver, notice that you are developing symptoms similar to addiction, leading to a desire for high doses of Stalevo and other medicines used to treat Parkinson’s disease.
Inform your doctor if you or your family/caregiver notice that you are developing urges or a tendency to behave in ways that are unusual for you or that you cannot resist the impulse, drive, or temptation to carry out certain activities that may harm you or others. These behaviours are known as impulse control disorders and may include gambling addiction, compulsive eating, excessive spending, or abnormally increased sexual urges or preoccupation with increased sexual thoughts or sensations. Your doctor may need to review your treatment.
During long-term treatment with Stalevo, your doctor may carry out blood tests regularly.
If you are due to undergo surgery, you must inform your doctor that you are taking Stalevo.
Stalevo is not recommended for the treatment of extrapyramidal symptoms (e.g., involuntary movements, restlessness, muscle rigidity, and muscle contractions) caused by other medicines.
Children and adolescents
Experience with the use of Stalevo in patients under 18 years of age is limited. Therefore, its use is not recommended in children or adolescents.
Taking Stalevo with other medicines
Inform your doctor or pharmacist if you are taking, have recently taken, or might need to take any other medicines.
Do not take Stalevo if you are taking certain medicines to treat depression (combinations of selective MAO-A and MAO-B inhibitors, or non-selective MAO inhibitors).
Stalevo may increase the effect, and also the adverse effects, of certain medicines. These include:
- medicines used to treat depression, such as moclobemide, amitriptiline, desipramine, maprotiline, venlafaxine, and paroxetine
- rimiterol and isoprenaline, used to treat respiratory diseases
- adrenaline, used for severe allergic reactions
- noradrenaline, dopamine, and dobutamine, used to treat heart conditions and low blood pressure
- alpha-methyldopa, used to treat high blood pressure
- apomorphine, used to treat Parkinson’s disease.
Certain medicines may reduce the effects of Stalevo. These medicines are:
- dopamine antagonists used to treat mental disorders, nausea, and vomiting
- phenytoin, used to prevent seizures
- papaverine, used to relax muscles.
Stalevo may interfere with the gastrointestinal absorption of iron. Therefore, Stalevo should not be taken at the same time as iron supplements. If you take either, you should wait at least 2 to 3 hours before taking the other.
Taking Stalevo with food and drink
- Stalevo may be taken with or without food.
- In some patients, Stalevo may not be well absorbed if taken with high-protein foods (meats, fish, dairy products, cereals, and nuts) or shortly after eating them. Consult your doctor if you think this applies to you.
Pregnancy, breastfeeding, and fertility
If you are pregnant or breastfeeding, think you may be pregnant, or plan to become pregnant, consult your doctor or pharmacist before taking this medicine.
You must not breastfeed while being treated with Stalevo.
Driving and use of machines
Stalevo may lower your blood pressure, which could cause dizziness or fainting. Therefore, take special care when operating tools or machinery.
If you feel very tired or notice that you fall asleep suddenly, wait until you are fully awake again before driving or doing anything else that requires alertness. Otherwise, you may put yourself and others at risk of a serious or even fatal accident.
Stalevo contains sucrose
Stalevo contains sucrose (2.3 mg/tablet). If your doctor has informed you that you have an intolerance to certain sugars, consult him before taking this medicine.
3. How to take Stalevo
Follow exactly the instructions given by your doctor or pharmacist for taking this medicine. If in doubt, consult your doctor or pharmacist again.
Adults and elderly:
- Your doctor will tell you the exact number of Stalevo tablets to take each day.
- The tablets must not be split or divided into smaller pieces.
- Take only one tablet at a time.
- Depending on your response to treatment, your doctor may instruct you to increase or decrease the dose.
- If you are taking Stalevo 200 mg/50 mg/200 mg tablets, do not take more than 7 tablets per day.
Talk to your doctor or pharmacist if you think the effect of Stalevo is too strong or too weak, or if you experience any possible adverse effects.
To open the bottle for the first time: open the closure by pressing with your thumb on the seal until it breaks. See Figure 1. | Figure 1
|
If you take more Stalevo than you should
If you have accidentally taken more Stalevo tablets than you should, speak to your doctor or pharmacist immediately. In case of overdose, you may feel dizzy or agitated, your heart rate may be slower or faster than normal, or the colour of your skin, tongue, eyes, or urine may change.
If you forget to take Stalevo
Do not take a double dose to make up for forgotten doses.
If more than 1 hour remains until the next dose:
Take one tablet as soon as you remember, and take the next one at the usual time.
If less than 1 hour remains until the next dose:
Take one tablet as soon as you remember, wait 1 hour, and then take another tablet. After that, continue as usual.
There must always be an interval of 1 hour between doses of Stalevo to avoid possible adverse effects.
If you stop taking Stalevo
Do not stop taking Stalevo unless your doctor tells you to do so. In such a case, your doctor may need to adjust the dose of your other Parkinson's medications, especially levodopa, to ensure adequate symptom control. If you abruptly stop taking Stalevo and other Parkinson's medications, you may experience unwanted adverse effects.
If you have any further questions about the use of this medicine, ask your doctor or pharmacist.
4. Possible adverse effects
Like all medicines, this medicine can cause adverse effects, although not everyone experiences them. Many of these can be relieved by adjusting the dose.
If you experience any of the following symptoms during treatment with Stalevo, contact your doctor immediately:
- Severe muscle stiffness or violent muscle contractions, tremors, agitation, confusion, fever, rapid pulse, or large fluctuations in blood pressure. These may be symptoms of neuroleptic malignant syndrome (NMS, a rare but serious reaction to medicines used to treat disorders of the central nervous system) or rhabdomyolysis (a rare and serious muscle disorder).
- Allergic reaction with signs such as hives, itching, rash, and swelling of the face, lips, tongue, or throat. This reaction may cause difficulty breathing or swallowing.
Very common (may affect more than 1 in 10 people):
- Involuntary movements (dyskinesias)
- Feeling unwell (nausea)
- Harmless reddish-brown discoloration of the urine
- Muscle pain
- Diarrhea
Common (may affect up to 1 in 10 people):
- Fainting or collapse due to low blood pressure, hypertension
- Worsening of Parkinsonism symptoms, dizziness, drowsiness
- Vomiting; abdominal pain and discomfort; heartburn; dry mouth; constipation
- Difficulty sleeping; hallucinations; confusion; abnormal dreams (including nightmares); fatigue
- Changes in mental state, including memory problems, anxiety, and depression (possibly with suicidal thoughts)
- Heart or artery problems (e.g., chest pain), irregular heartbeat
- More frequent falls
- Labored breathing
- Increased sweating, rashes
- Muscle cramps, swelling of the legs
- Blurred vision
- Anaemia
- Decreased appetite, weight loss
- Headache, joint pain
- Urinary tract infections
Uncommon (may affect up to 1 in 100 people):
- Heart attack
- Intestinal bleeding
- Changes in blood cell counts that may lead to bleeding; abnormalities in liver function tests
- Seizures
- Feeling of restlessness
- Psychotic symptoms
- Colitis (inflammation of the colon)
- Changes in pigmentation other than in urine (e.g., skin, nails, hair, sweat)
- Difficulty swallowing
- Inability to urinate
Frequency not known (cannot be estimated from available data):
A desire to take higher doses of Stalevo than needed to control motor symptoms, known as dopamine dysregulation syndrome. Some patients may experience severe abnormal involuntary movements (dyskinesias), mood changes, or other adverse effects after taking high doses of Stalevo.
The following adverse effects have also been reported:
- Hepatitis (inflammation of the liver)
- Itching
You may experience the following adverse effects:
- Inability to resist the impulse to carry out an action that could be harmful, which may include:
- a strong urge to gamble excessively despite serious personal or family consequences
- increased or altered interest in sex and behaviour that is concerning to you or others, such as increased sexual urges
- excessive or uncontrolled shopping or spending
- eating excessively (consuming large amounts of food in short periods of time) or compulsive eating (eating more food than usual and more than needed to satisfy hunger).
Inform your doctor if you experience any of these behaviours. They will discuss how to manage or reduce these symptoms.
Reporting of adverse effects
If you experience any adverse effect, talk to your doctor or pharmacist, even if it is a possible adverse effect not listed in this leaflet. You can also report them directly through the national reporting system listed in Annex V. By reporting adverse effects, you help provide more information on the safety of this medicine.
5. Storage of Stalevo
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date stated on the packaging following EXP. The expiry date refers to the last day of the month indicated.
No special storage conditions are required.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines and packaging you no longer need. This will help protect the environment.
6. Contents of the pack and other information
Composition of Stalevo
- The active substances in Stalevo are levodopa, carbidopa and entacapone.
- Each Stalevo 200 mg/50 mg/200 mg tablet contains 200 mg of levodopa, 50 mg of carbidopa and 200 mg of entacapone.
- The other components of the tablet core are sodium croscarmellose, magnesium stearate, maize starch, mannitol (E 421) and povidone (E 1201).
- The components of the film coating are glycerol 85 percent (E 422), hypromellose, magnesium stearate, polysorbate 80, red iron oxide (E 172), sucrose and titanium dioxide (E 171).
Nature of the product and contents of the pack
Stalevo 200 mg/50 mg/200 mg: red-brownish, oval, film-coated tablets without a break line, marked with "LCE 200" on one side.
There are five different pack sizes for Stalevo 200 mg/50 mg/200 mg (10, 30, 100, 130 or 175 tablets). Some pack sizes may not be marketed.
Marketing Authorization Holder and Manufacturer
Orion Corporation
Orionintie 1
FI-02200 Espoo
Finland
For further information about this medicinal product, please contact the local representative of the Marketing Authorization Holder.
Belgium/Belgium/Belgium Orion Pharma BVBA/SPRL Tel/Tel: +32 (0)15 64 10 20 | Lithuania UAB Orion Pharma Tel.: +370 5 276 9499 |
Finland Orion Corporation Tel.: +358 10 4261 | Luxembourg/Luxembourg Orion Pharma BVBA/SPRL Tél/Tel: +32 (0)15 64 10 20 |
Czech Republic Orion Pharma s.r.o. Tel: +420 234 703 305 | Hungary Orion Pharma Kft. Tel.: +36 1 239 9095 |
Denmark Orion Pharma A/S Tlf: +45 8614 0000 | Malta Orion Corporation Tel: +358 10 4261 |
Germany Orion Pharma GmbH Tel: +49 40 899 6890 | Netherlands Orion Pharma BVBA/SPRL Tél/Tel: +32 (0)15 64 10 20 |
Estonia Orion Pharma Eesti OÜ Tel: +372 66 44 550 | Norway Orion Pharma AS Tlf: +47 40 00 42 10 |
Greece Orion Pharma Hellas M.E.Π.E Tel: +30 210 980 3355 | Austria Orion Pharma GmbH Tel: +49 40 899 6890 |
Spain Orion Pharma S.L. Tel: +34 91 599 86 01 | Poland Orion Pharma Poland Sp z.o.o. Tel.: +48 22 8333177 |
France Centre Spécialités Pharmaceutiques Tel: +33 (0)1 47 04 80 46 | Portugal Orionfin Unipessoal Lda Tel: +351 21 154 68 20 |
Croatia Orion Pharma d.o.o. Tel: +386 (0)1 600 8015 | Romania Orion Corporation Tel: +358 10 4261 |
Ireland Orion Pharma (Ireland) Ltd. c/o Allphar Services Ltd. Tel: +353 1 428 7777 | Slovenia Orion Pharma d.o.o. Tel: +386 (0)1 600 8015 |
Iceland Vistor hf. Tel: +354 535 7000 | Slovakia Orion Pharma s.r.o Tel: +420 234 703 305 |
Italy Orion Pharma S.r.l. Tel: +39 02 67876111 | Finland/Sweden Orion Corporation Puh./Tel: +358 10 4261 |
Cyprus Lifepharma (ZAM) Ltd Tel.: +357 22056300 | Sweden Orion Pharma AB Tel: +46 8 623 6440 |
Latvia Orion Corporation Orion Pharma parstavnieciba Tel: +371 20028332 | United Kingdom Orion Pharma (UK) Ltd. Tel: +44 1635 520 300 |
Date of the most recent revision of this leaflet:
Other sources of information
Detailed information on this medicine is available on the European Medicines Agency website: http://www.ema.europa.eu
